Spero Therapeutics Shares Are Trading Higher After the Company Announced the Publication of Data From Its Phase 1 Clinical Trial, Which Assessed the Intrapulmonary Pharmacokinetics of SPR719.
Spero Therapeutics Shares Are Trading Higher After the Company Announced the Publication of Data From Its Phase 1 Clinical Trial, Which Assessed the Intrapulmonary Pharmacokinetics of SPR719.
spero therapeutics股价上涨，原因是该公司宣布了来自其第1期临床试验数据的发表，该试验评估了SPR719的肺内药代动力学。
Spero Therapeutics Shares Are Trading Higher After the Company Announced the Publication of Data From Its Phase 1 Clinical Trial, Which Assessed the Intrapulmonary Pharmacokinetics of SPR719.
spero therapeutics股价上涨，原因是该公司宣布了来自其第1期临床试验数据的发表，该试验评估了SPR719的肺内药代动力学。